BRIA Market Analysis

Wall Street coverage

third-party context

Wall Street coverage

$2.75median target· current $1.39 (+97.8%)1 analyst

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

49 articles · sorted by date
Page 1 of 3 · 49 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratioForward 21.28
EPS (TTM)$-0.01-96.4% YoY
Profit margin-0.0%CONSUMER CYCLICAL
Market cap$35.6MMicro cap

Valuation

Forward P/E
21.28
PEG ratio
P/B
2.54
P/S (TTM)
0.73
EV/EBITDA
31.66

Profitability & growth

ROE (TTM)
-0.1%
Operating margin
-0.0%
Revenue growth YoY
-34.0%
Dividend yield
Beta
Last earnings
Feb 25, 2026 · Estimate $0.00 · Reported $0.00
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About BrilliA Inc

Company profile

BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.

Classification

Exchange
AMEX
Country
USA
Currency
USD

Company profile

HQ
51 CUPPAGE ROAD, SINGAPORE, SINGAPORE
Fiscal year end
March
Latest quarter
Mar 31, 2026
Market cap$35.6M
Shares outstanding$25.0M
52W high$2.30
52W low$1.07

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer